DCF Advisers LLC Acquires New Position in Regeneron Pharmaceuticals, Inc. $REGN

DCF Advisers LLC acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 9,250 shares of the biopharmaceutical company’s stock, valued at approximately $5,768,000. Regeneron Pharmaceuticals accounts for approximately 1.0% of DCF Advisers LLC’s portfolio, making the stock its 14th biggest position.

Other hedge funds have also modified their holdings of the company. WPG Advisers LLC raised its position in Regeneron Pharmaceuticals by 312.5% in the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 25 shares in the last quarter. SHP Wealth Management acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $26,000. Western Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth approximately $26,000. Titan Wealth CI Ltd purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth approximately $29,000. Finally, Mowery & Schoenfeld Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals in the second quarter valued at approximately $29,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: The FDA approved Pasatru as the first and only treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare disorder involving abnormal bone formation in soft tissues. In the placebo-controlled OPTIMA trial, Pasatru reduced new heterotopic ossification lesions by at least 90% at 56 weeks and significantly reduced clinician-assessed flare-ups. The approval adds a potential commercial product and strengthens Regeneron’s rare-disease portfolio. Reuters FDA approval article
• Positive Sentiment: The Pasatru approval is supported by meaningful clinical efficacy in a condition with limited treatment options, potentially giving Regeneron pricing and market-entry advantages in a highly specialized market. The financial contribution may initially be limited by FOP’s very small patient population, but the regulatory milestone can improve long-term pipeline value. Pasatru approval announcement
• Neutral Sentiment: Regeneron announced upcoming investor conference presentations by management. The events could provide additional details on Pasatru’s launch, the broader pipeline and financial outlook, but the announcement itself does not change current earnings expectations. Regeneron investor conference announcement
• Positive Sentiment: Leerink Partners raised its price target for REGN to $824, signaling continued analyst support for the shares, although the target may not fully reflect the latest trading level. Leerink Partners price target article
• Negative Sentiment: Several law firms publicized securities class actions and a September 14, 2026 lead-plaintiff deadline concerning allegations that Regeneron misrepresented risks surrounding the Phase 3 fianlimab-Libtayo melanoma trial. The trial’s failure reportedly erased approximately $11 billion in market value, creating litigation costs, reputational risk and uncertainty around the oncology pipeline. These notices largely repeat the same underlying allegations rather than represent new operational developments. Regeneron class action notice

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Kathryn Guarini sold 400 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $320,000.00. Following the transaction, the director directly owned 603 shares in the company, valued at approximately $482,400. This trade represents a 39.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $640,000.00. Following the completion of the transaction, the director directly owned 1,703 shares in the company, valued at $1,362,400. The trade was a 31.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 1,400 shares of company stock worth $1,090,030. 6.97% of the stock is owned by insiders.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $840.84 on Thursday. The stock’s 50-day moving average is $688.35 and its two-hundred day moving average is $715.30. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. Regeneron Pharmaceuticals, Inc. has a 1 year low of $541.00 and a 1 year high of $844.92. The firm has a market cap of $86.57 billion, a price-to-earnings ratio of 20.78, a PEG ratio of 1.38 and a beta of 0.22.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating the consensus estimate of $10.16 by $4.13. The business had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The business’s quarterly revenue was up 16.7% on a year-over-year basis. During the same period in the previous year, the business earned $12.81 EPS. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th will be paid a $0.94 dividend. The ex-dividend date is Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. Regeneron Pharmaceuticals’s payout ratio is currently 9.29%.

Wall Street Analyst Weigh In

REGN has been the topic of a number of analyst reports. Sanford C. Bernstein upgraded shares of Regeneron Pharmaceuticals to a “hold” rating in a report on Wednesday, July 29th. Canaccord Genuity Group cut their price target on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. Wells Fargo & Company increased their price objective on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an “equal weight” rating in a report on Friday, July 31st. Guggenheim raised their target price on Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Finally, Barclays decreased their target price on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating for the company in a research note on Thursday, April 30th. Sixteen equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $801.70.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.